checkAd

     413  0 Kommentare Sobi opens North American operations

    Swedish Orphan Biovitrum AB (publ) (Sobi) today formally opened the company's new North American office in Waltham, Massachusetts with a ribbon cutting ceremony arranged in collaboration with the Massachusetts Life Sciences Center (MLSC).

    "North America is an increasingly important region for Sobi, and building our team in the Boston area supports us in our efforts to better address the needs of patients and healthcare providers throughout the United States and Canada, " says Geoffrey McDonough, Sobi's President & CEO. "We are delighted to partner and collaborate with the Massachusetts Life Sciences Center as we build and grow in the years to come."

    Ceremony attendees included local officials and legislators, MLSC President & CEO Susan Windham-Bannister, Ph.D., President, National Organization of Rare Disorders, Dr. Peter Saltonstall, Manager of Business Development, Massachusetts Office of International Trade & Investment Brittany McDonough, MassBio Director of Economic Development & Global Affairs Peter Abair, as well as Sobi's President & CEO, Geoffrey McDonough, and President North America, Rami Levin.

    "Thanks to our growth strategy of investing in education, innovation and infrastructure, and the extensive outreach efforts of the Massachusetts Life Sciences Center, Massachusetts has become the destination of choice for international life sciences companies that want to have a presence in the U.S. market," said Governor Deval Patrick. "We welcome Sobi to their new offices in Waltham and look forward to partnering with them as they grow."

    "Massachusetts has one of the largest concentrations of biotech activity in the world. The region has established a broad-based biotech industry segment, and with Massachusetts as a major driver for global biotechnology innovation there is a strong talent pool here. This is essential for us as we grow our North American business," says Rami Levin, President, Sobi North America.

    Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In North America, the Company mainly focuses on inflammatory, genetic, and metabolic diseases. Earlier this year, Sobi assumed direct responsibility for the commercialization of its proprietary product, Orfadin in North America. Orfadin is the only FDA approved therapy for use as an adjunct to dietary restriction of tyrosine and phenylalanine for the treatment of hereditary tyrosinemia type 1 (HT-1).

    Seite 1 von 3


    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    Sobi opens North American operations Swedish Orphan Biovitrum AB (publ) (Sobi) today formally opened the company's new North American office in Waltham, Massachusetts with a ribbon cutting ceremony arranged in collaboration with the Massachusetts Life Sciences Center (MLSC). "North …